Rituximab in Antimelanoma Differentiation-Associated Protein-5 Dermatomyositis with Interstitial Lung Disease

In this paper, we report a challenging case of a middle-age woman who developed antimelanoma differentiation-associated protein-5 dermatomyositis (anti-MDA5 DM) with interstitial lung disease (ILD) and was successfully treated with rituximab (RTX), after failure of a first-line therapy.

Detalles Bibliográficos
Autores principales: Scirocco, Chiara, Gubbiotti, Andreina, Sebastiani, Alfredo, Sebastiani, Gian Domenico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7654211/
https://www.ncbi.nlm.nih.gov/pubmed/33204565
http://dx.doi.org/10.1155/2020/8145790

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7654211/
https://www.ncbi.nlm.nih.gov/pubmed/33204565
http://dx.doi.org/10.1155/2020/8145790

Ejemplares similares